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Abstract: Ulcerative colitis (UC) is an immune-mediated disease of the colon that is character-
ized by diffuse and continuous inflammation contiguous from the rectum. Half of UC patients 
have inflammation limited to the distal colon (proctitis or proctosigmoiditis) that primarily 
causes symptoms of bloody diarrhea and urgency. Mild-to-moderate distal UC can be effectively 
treated with topical formulations (rectal suppositories, enemas, or foam) of mesalamine or 
steroids to reduce mucosal inflammation and alleviate symptoms. Enemas or foam formulations 
adequately reach up to the splenic flexure, have a minimal side-effect  profile, and induce remis-
sion alone or in combination with systemic immunosuppressive therapy. Herein, we compare 
the efficacy, cost, patient tolerance, and side-effect profiles of steroid and mesalamine rectal 
formulations in distal UC. Patients with distal mild-to-moderate UC have a remission rate of 
approximately 75% (NNT =2) after treatment for 6 weeks with mesalamine enemas. Rectal 
budesonide foam induces remission in 41.2% of patients with mild-to-moderate active distal 
UC compared to 24% of patient treated with placebo (NNT =5). However, rectal budesonide 
has better patient tolerance profile compared to enema formulations. Despite its favorable 
efficacy, safety, and cost profiles, patients and physicians significantly underuse topical treat-
ments for treating distal colitis. This necessitates improved patient education and physician 
familiarity regarding the indications, effectiveness, and potential financial and tolerability 
barriers in using rectal formulations.
Keywords: inflammatory bowel disease, treatment cost effectiveness, Crohn’s disease, 
ulcerative colitis, colon mucosa, proctitis suppositories, topical immunosuppressive therapy
Introduction
Inflammatory bowel disease (IBD) is a chronic immune-mediated disease of the 
gastrointestinal tract that affects more that 1.6 million Americans.1,2 Ulcerative colitis 
(UC) is characterized by diffuse, continuous, superficial, and ulcerating inflammation 
confined to the colon that causes rectal bleeding, diarrhea, and abdominal pain. The 
current working model of IBD pathogenesis posits a dysregulated immune response 
against gut microbiota in the presence of genetic defects, leading to exaggerated self-
injurious inflammatory responses. Genome-wide association studies have identified 
IBD susceptibility genes, the majority of which are immunoregulatory.3,4 UC can 
have varied distribution and severity. Ulcerative proctitis (UP) and ulcerative procto-
sigmoiditis (UPS), defined as disease extending 15 and 40 cm from the anal verge, 
respectively, are seen in approximately 50% of UC patients.5 Left-sided colitis, seen 
in around 30% of UC patients, involves continues inflammation from the anus to the 
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splenic flexure, and only 20% of UC patients have extensive 
colitis or pancolitis.6
The mainstay therapy for IBD involves anti-inflammatory 
immunosuppression dictated by the severity and location of 
disease. Moderate-to-severe disease is typically treated with 
immunosuppressive medications such as azathioprine, anti-
TNFα, and more recently, anti-integrin agents.7 Oral cortico-
steroids are limited to treating acute flares and have limited 
efficacy in maintaining remission.8 Rectally administered 
therapies can be effective in distal colitis and include sup-
positories for proctitis or enemas and foam preparations for 
proctosigmoiditis and left-sided colitis. However, because of 
lack of knowledge and familiarity regarding efficacy, safety, 
and patient tolerance, topical therapies are often underused in 
UC patients. The Swiss Inflammatory Bowel Disease Cohort 
study reports that only 26% of patients with mild-to-moderate 
proctitis were treated with topical therapy and only 13% of 
patients with active extensive colitis received treatment that 
included topical rectal therapy.9
Herein, we provide an updated literature review of the 
effectiveness, safety, tolerability, and cost of topical treat-
ments for distal inflammatory colitis. We compare different 
formulations of topical therapies (ie, suppositories, enemas, 
and rectal foam) with a particular focus on how budesonide, a 
specific corticosteroid, compares to other treatments. Impor-
tantly, we provide a framework and treatment algorithm for 
distal UC.
Available topical therapies for 
distal colitis
Common therapies for the treatment of UP and UPS include 
5-aminosalicylic acid (5-ASA) and steroids. Mesalamine and 
other 5-ASA substances are the first-line choice in treating 
mild-to-moderate UC, regardless of the physical extent of 
disease. Mesalamine has multiple reported anti-inflammatory 
effects that include inhibiting leukotriene and IL-1 produc-
tion, impairing TNFα and NF-κB transcription signaling 
and having antioxidant properties by acting as a free-radical 
scavenger.10 Additionally, mesalamine reduces mucosal 
inflammation by acting on mucosal colonic epithelial cells 
and infiltrating leukocytes, with its clinical efficacy therefore 
correlating with its local concentration in the gut.
Oral mesalamine is effective and can induce remission 
in active UC; however, delivery of the active agent to the 
inflamed distal colon is limited. Intolerance to the sulfapyri-
dine moiety of sulfasalazine is fairly common and may result 
in nausea, vomiting, dyspepsia, anorexia, and headache. More 
severe but less common adverse effects for sulfasalazine 
and melamine oral formulations include allergic reactions, 
pancreatitis, hepatotoxicity, drug-induced connective tissue 
disease, bone marrow suppression, interstitial nephritis, and 
hemolytic anemia or megaloblastic anemia.11 In a multicenter, 
double-blind study, patients with mild-to-moderate active 
UC were randomized to either oral mesalamine or placebo 
and were followed at 3- and 6-week time points. At 3 weeks, 
remission rates (defined by improved stool frequency, rec-
tal bleeding, and sigmoidoscopic findings) were 32% for 
patients treated with 2.4 g/d of mesalamine vs 9% in the 
placebo arm, and at 6 weeks, efficacy increased to 49% vs 
23%, respectively.12 However, in mild-to-moderate UP and 
UPS, topically administered 5-ASA (ie, suppository, enema, 
or rectal foam preparations) can be more efficacious both 
at generating a response and inducing remission than oral 
5-ASA. A randomized, double-blinded trial demonstrated 
endoscopic remission and decreased rectal bleeding in 
patients with mild-to-moderate UC with rectal inflammation 
after a 4-week treatment period with 1 g mesalazine supposi-
tory once daily as compared to placebo (81.5% vs 29.7%, 
P<0.0001).13 However, suppositories rarely extend beyond 
10–15 cm from the rectum, making them less attractive as a 
rectal formulation. A meta-analysis comparing rectal 5-ASA 
to placebo in patients with distal UC demonstrated that rectal 
5-ASA was superior to placebo for inducing symptomatic 
remission (OR: 8.3, 95% CI: 4.3–16.1) and endoscopic 
remission (OR: 5.3, 95% CI: 3.2–8.9).14
Practice guidelines recommend using topical mesalamine 
agents as first line compared to topical steroids or oral ami-
nosalicylates for the treatment of distal mild-to-moderate 
UC, and the combination of oral and topical aminosalicylates 
is more effective than either alone. 15 In addition, practice 
guidelines recommend mesalamine suppositories or enemas 
as the preferred agents to maintain remission in distal mild-to-
moderate UC. Mesalamine suppositories maintain remission 
in 90% of patients with mild-to-moderate UP at 1 year, while 
mesalamine enemas maintain remission in 72% of patients 
with mild-to-moderate UPS when administered every other 
day at 1 year.16,17
Topical steroids are an alternative treatment for distal 
colitis, particularly if patients fail or do not tolerate 5-ASA 
therapy. They have long-ranging anti-inflammatory effects 
through various mechanisms, including expression of anti-
inflammatory cytokine IL-10, inhibition of histone acetylation 
and immune cell apoptosis, and reduced signaling of inflamma-
tory transcription factors such as NF-κB and AP-1. Oral corti-
costeroids are efficacious in controlling acute colitis flares, but 
16% of patients show no response and 30% show only a partial 
response.8 Moreover, oral steroid use can have numerous side 
effects, spanning multiple organ systems: acne, moon facies, 
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infection, hypertension, and hirsutism being among the most 
common. Notable effects from long-term corticosteroid use are 
hypertension, diabetes, adrenal insufficiency, osteoporosis, and 
psychosis.18 Given the side-effect profile, oral steroid therapy is 
limited to short-treatment intervals in patients with moderate-
to-severe disease rather than long-term maintenance.16 Rectally 
applied steroids offer advantages as compared to orally admin-
istered drugs because they offer a more targeted treatment to 
the areas of active inflammation and generally have fewer 
systemic effects than oral corticosteroid use.19,20 Budesonide 
is a lipophilic agent with lower systemic bioavailability, which 
can potentially cause lower systemic side effects.
Efficacy of budesonide rectal foam
Budesonide, a high-potency, nonhalogenated, second-gener-
ation corticosteroid, can be used either topically or orally in 
patients with UC. The pharmacokinetic profile of budesonide 
rectal foam, specifically the extent of spread and length of 
persistence in the colon, make it an efficacious topical treat-
ment. Using [99Tcm]-labeled budesonide foam in patients with 
moderate proctosigmoiditis or left-sided colitis,  Brunner et al21 
determined that budesonide spread 25.4±10.3 cm, reached 
the sigmoid colon in all patients, and had a mean colonic 
residence time of 5.3 hours. Sandborn et al19 compared rectal 
budesonide foam to placebo in two randomized, double-blind, 
side-by-side trials utilizing 546 patients with mild-to-moderate 
UP or UPS. All patients had disease extending at least 5 cm, 
but no >40 cm from the anal verge. The budesonide treatment 
arm received 2 mg/mL two times daily (BID) dosing of the 
foam for 2 weeks and then was switched to once daily dosing 
for 4 weeks. The primary end point was remission, defined 
by Mayo Score ≤1, no rectal bleeding, and either no change 
or an improvement in stool frequency. A combined 41.2% 
of patients demonstrated remission as compared to 24% of 
the placebo patients (P<0.0001). Interestingly, in subgroup 
analysis, budesonide rectal foam was still superior to placebo 
regardless of concurrent use of <4.8 g/d of oral mesalamine, 
suggesting that budesonide foam can have additive treatment 
effects in patients already receiving oral mesalamine treatment.
Comparison of budesonide with other corticosteroid rec-
tal foam therapies, however, did not demonstrate increase in 
efficacy (Table 1). Bar-Meir et al20 investigated the  differences 
between budesonide and hydrocortisone administration as 
rectal foam. This randomized, parallel-group, multicenter 
Table 1 Comparison of important clinical trials of melamine or steroid topical formulations to treat mild-to-moderate UC








At 6 weeks, with 1.6 g/d: 
43% vs 23% (P=0.03)
At 6 weeks, with 2.4 g/d: 




1.6 g/d vs 2.4 g/d of 
mesalamine
6 Scores for stool frequency, rectal 
bleeding, functional assessment, 
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4 Endoscopic remission: scores of 0 or 
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41% vs 24% (P<0.0001) 72% 
proctosigmoiditis
28% proctitis
2 mg/mL BID × 
2 weeks,  
then 2 mg/mL  
daily × 4 weeks
6 Endoscopy subscore ≤1, rectal 
bleeding subscore of 0, and 
improvement or no change from 
baseline in the stool frequency 












(2 mg/20 mL) once 
nightly
Hydrocortisone 
foam (100 mg/ 
15 mL) once nightly
8 Defined by a disease activity index 
score of 3 or less
20
Note: aConcomitant use of oral mesalamine at a stable dosage of up to 2 g/d was permitted.
Abbreviations: BID, two times daily; UC, ulcerative colitis; CAI, clinical disease activity; EI, endoscopic index; IBDQ, inflammatory bowel disease questionnaire; DAI, disease 
activity index.





clinical trial included 251 patients with active mild-to-
moderate UPS and demonstrated similar efficacy (remission 
rates of approximately 50%) following a 6-week treatment 
period with either steroid rectal foam. Thus, for patients with 
distal UC, hydrocortisone or budesonide rectal foam can be 
an efficacious therapeutic choice.
Patient safety, tolerance, and use of 
budesonide rectal foam
Multiple studies have shown that budesonide foam is safe 
for administration in UP and UPS, with minimal adverse 
effects and rare serious adverse effects. These adverse 
events are thought to be secondary to intestinal absorp-
tion of budesonide.21 The most common adverse effects 
include headache, nausea, decreased serum cortisol levels, 
and abdominal pain.18 In the randomized, side-by-side trial 
by Sandborn et al,19 serious adverse events occurred in 
1%–2% of patients, rates that were not significantly higher 
than placebo and had no clear association with budesonide. 
Budesonide can cause transient decrease in cortisol levels 
in 16% of patients when administered as a BID dosing for 
2 weeks. However, by the end of the 6-week trial, 94.2% of all 
patients in the budesonide treatment arm had normal cortisol 
levels. Altogether, the data support the fact that budesonide 
rectal foam is a safe treatment with minimal adverse events 
associated with its use.
Rectal foam formulations have been designed to provide 
a more uniform delivery to the left colon and to optimize 
retention. One advantage in using foam as opposed to 
enemas is the sheer volume of therapy (20–25 mL for foam 
vs 60–100 mL for enema). Because of the higher volume, 
urgency and abdominal/rectal discomfort tend to be more 
associated with enemas. A recent double-blind, double-
dummy randomized trial by Gross et al22 compared remission 
rates and overall patient tolerability/satisfaction between 
budesonide enemas vs foam in the treatment of active UP or 
UPS. The study highlighted that though the overall remission 
rates were similar between the two treatment modalities (66% 
for enema vs 60% for foam), there was an overwhelming 
preference for the foam formulation (84%). This disparity in 
patient preference/satisfaction was due in part to higher rates 
of retention while using enemas as opposed to foam (39% 
compared to 11%, respectively), more unpleasant feelings 
(36% compared to 12%, respectively), and more rectal pain 
(18% compared to 10%, respectively).
Instructions to patients should include the importance 
of emptying bowels before administering the rectal foam 
and stress lubrication of the applicator. Patients should be 
advised to warm the canister in their hands while shaking 
it vigorously for 10–15 seconds prior to use and that appli-
cation of the rectal foam can be done while in a standing, 
lying, or sitting position. Additionally, application of rectal 
foam should be performed in the morning and before bed 
the first 2 weeks of treatment, and then once daily in the 
evening for the next 4 weeks. Budesonide is metabolized via 
CYP3A4, and therefore, patients should be advised to avoid 
ketoconazole or grapefruit juice during treatment to prevent 
increased exposure.
Available formulations and cost of topical 
therapies
Both ASA and steroids come in different formulations, 
including suppositories, enemas, and more recently, foams. 
Efficacies and costs of these various formulations are sum-
marized in Table 1. The extent and severity of UC and treat-
ment response and duration among different study patient 
populations varied; therefore, direct comparisons of efficacy 
and overall health care cost among the different medications 
have to be done in relative terms. The extent and severity of 
the colonic inflammation dictates the formulation of topical 
therapy. Suppositories are more commonly used in mild-
to-moderate cases of proctitis, while enemas and foams are 
typically used in more extensive disease, such as proctosig-
moiditis and left-sided colitis. Immunomodulator treatment 
is often used in moderate-to-severe UC or mild-to-moderate 
disease that had minimal response to mesalamine formula-
tions. Topical therapy in combination with immunomodula-
tory treatment provided further symptoms control in patients 
with active distal colitis.15
In the United States, the price of topical, oral, and paren-
teral biologic therapy for IBD varies and ranges from <$100 
per month for sulfasalazine and azathioprine to several 
thousand dollars for biologic therapy (Table 2). Budesonide 
rectal foam is sold in kits that contain a canister of 33.4 g and 
applicators that deliver 14 2 mg doses. A 6-week course of 
budesonide foam is generally recommended to induce remis-
sion, with twice-daily dosing for the first 2 weeks, followed 
by once-a-day dosing for the remaining 4 weeks. Each of 
the budesonide foam kits costs approximately $320, making 
the recommended 6 week course cost $1,280. Mesalamine 
suppositories and enemas despite being on the market for 
decades cost $1,000–$1,600 per month when used once daily. 
Furthermore, an 80 kg person receiving 5 mg/kg of infliximab 
generates a drug cost of almost $47,000 in the first year of 
treatment.23 Similarly, vedolizumab, a gut-selective block-
ade of lymphocyte trafficking, is administered in 300 mg 
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infusions every 8 weeks and a loading dose24. One 300 mg 
vedolizumab infusion costs $5,800, and the treatment during 
the first year costs $49,000.
Conclusion
Approximately half of patients with UC have distal colitis, 
causing symptoms of bloody diarrhea, tenesmus, and rectal 
pain. Despite the favorable efficacy, safety, and cost profile 
of topical treatments, only one in four patients with mild-
to-moderate distal colitis is prescribed topical therapy. In 
mild-to-moderate UP or UPS, topical therapy with 5-ASA is 
recommended as a first-line agent and is cost-effective over 
other treatment options. Overall, mesalamine enemas can 
induce clinical and endoscopic remission in three out of four 
patients with minimal side effects. Advantages of topical ther-
apy include a quicker response time and less frequent dosing 
schedule than oral therapy, as well as less systemic absorption. 
The choice of topical therapy is primarily guided by patient 
preference as well as by the proximal extent of disease. Some 
patients may achieve maximum benefit from combination of 
oral and topical therapy achieving clinical improvement, as 
well as an earlier response than either agent alone.25
Previous studies demonstrated that topical cortico-
steroids, whether hydrocortisone or budesonide, have 
not proven effective for maintaining remission in distal 
colitis.26,27 Recently, Sandborn et al19 demonstrated that 
rectal budesonide foam is effective at inducing remission in 
mild-to-moderate active UP or UPS and has better patient 
tolerability/satisfaction compared to enema formulations. 
Furthermore, in patients with incomplete response to topi-
cal or oral mesalamine, budesonide foam could be used in 
conjunction to induce remission. Alternatively, budesonide 
foam can be used as an adjunctive agent during acute flares 
in patients with distal colitis. Overall, it is important for 
physicians to understand and in turn educate patients about 
the effectiveness, safety, cost, and tolerability of topical 
therapies in active distal UC.
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